MDM2: current research status and prospects of tumor treatment

• Published in: Cancer cell international Vol. 24; no. 1; p. 170
• Main Authors: Yao, Yumei, Zhang, Qian, Li, Zhi, Zhang, Hushan
• Format: Journal Article
• Language: English
• Published: England BioMed Central 13.05.2024; BMC
• Subjects: Apoptosis; Breast cancer; Cancer therapies; Cell cycle; Chemotherapy; Cyclin-dependent kinases; DNA methylation; Drug delivery; Drug development; Drug interaction; Genes; Immune checkpoint inhibitors; Immunosuppressive agents; Immunotherapy; Kinases; Leukemia; Liver cancer; MDM2 protein; Mutation; p53 Protein; Phosphorylation; Proteins; Radiation; Review; Ubiquitination
• ISSN: 1475-2867; 1475-2867
• DOI: 10.1186/s12935-024-03356-8

Mousedouble minute 2 (MDM2) is one of the molecules activated by p53 and plays an important role in the regulation of p53. MDM2 is generally believed to function as a negative regulator of p53 by facilitating its ubiquitination and subsequent degradation. Consequently, blocked p53 activity often fails in damaged cells to undergo cell cycle arrest or apoptosis. Given that around 50% of human cancers involve the inactivation of p53 through genetic mutations, and directly targeting p53 through drug development has limited feasibility, targeting molecular regulation related to p53 has great potential and has become a research hotspot. For example, developing drugs that target the interaction between p53 and MDM2. Such drugs aim to reactivate p53 by targeting either MDM2 binding or p53 phosphorylation. Researchers have identified various compounds that can serve as inhibitors, either by directly binding to MDM2 or by modifying p53 through phosphorylation. Furthermore, a significant correlation exists between the expression of MDM2 in tumors and the effectiveness of immunotherapy, predominantly in the context of immune checkpoint inhibition. This review presents a comprehensive overview of the molecular characteristics of MDM2 and the current state of research on MDM2-targeting inhibitors. It includes a review of the impact of MDM2 targeting on the efficacy of immunotherapy, providing guidance and direction for the development of drugs targeting the p53-MDM2 interaction and optimization of immunotherapy.